Combination Therapies for the Treatment of Cancer
A combination therapy using a CDC7 kinase inhibitor and additional agents targets CDC7 kinase to enhance cancer treatment efficacy by inducing anti-proliferation and apoptosis, addressing the limitations of current therapies in treating HRD and platinum-resistant cancers.
Patent Information
- Application Number
- JP2022530007
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-19
- Filing Date
- 2020-07-17
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-07-17
AI Technical Summary
Current cancer therapies are inadequate in effectively targeting CDC7 kinase, which is crucial for DNA replication and DNA damage response, and its elevated expression is associated with poor prognosis in various cancers, necessitating new combination therapies that include CDC7 inhibitors.
A combination therapy involving a CDC7 kinase inhibitor, such as Compound 1, and one or more second therapeutic agents, including DNA damaging agents, tubulin binding agents, cell signaling modulators, HSP90 inhibitors, HDAC inhibitors, checkpoint inhibitors, and radiation therapy, to treat cancer by inhibiting CDC7 kinase activity.
The combination therapy effectively induces anti-proliferation and apoptosis in a wide range of cancers, enhancing treatment efficacy beyond individual treatments, particularly in HRD cancers and those resistant to platinum compounds.
Smart Images

Figure 0007594009000028 
Figure 0007594009000029 
Figure 0007594009000030
Abstract
Description
[Technical field]
[0001] The present disclosure relates to (i) Compound 1
[0002] [ka]
[0003] and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) one or more second therapeutic agents and / or second therapies. [Background technology]
[0004] CDC7 is a serine / threonine kinase that contributes to the initiation of DNA replication by phosphorylating MCM2. The kinase activity of CDC7 is controlled by its binding protein Dbf4 in a cell cycle-dependent manner. Recent studies have revealed that CDC7 is also involved in DNA damage response (DDR) and DNA replication, suggesting that CDC7 plays an important role in both cell proliferation in S phase and genome stability in DDR. Furthermore, elevated CDC7 expression has been reported in various cancers and is associated with poor prognosis, such as diffuse large B-cell lymphoma, oral squamous cell carcinoma, breast cancer, colon tumors, ovarian tumors and lung tumors.
[0005] Considering that CDC7 is involved in two important functions, DNA replication and DDR, CDC7 appears to be an important gene for cancer cell proliferation and survival, and inhibition of CDC7 is expected to induce anti-proliferation and apoptosis in a wide range of cancers, not limited to specific organ types. New cancer therapies, such as combination therapies including CDC7 inhibitors, are needed. Summary of the Invention
[0006] The present disclosure provides a therapeutically effective amount of (i) Compound 1
[0007] [ka]
[0008] and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) one or more second therapeutic agents and / or second therapies.
[0009] In some embodiments, the second therapeutic agent is selected from a DNA damaging agent, a tubulin binding agent, a cell signaling modulator, an HSP90 inhibitor, an HDAC inhibitor, a checkpoint inhibitor, an antimetabolite, etoposide, entinostat, obatoclax, and tunicamycin. In some embodiments, the second therapy is one or more radiation treatments.
[0010] In some embodiments, the disclosure provides a method of treating cancer in a patient in need thereof, comprising administering therapeutically effective amounts of (i) Compound 1, one or more second therapeutic agents, and a second treatment (i.e., radiation treatment).
[0011] The disclosure also provides pharmaceutical compositions comprising Compound 1 and / or a tautomer or a pharma- ceutically acceptable salt or hydrate thereof, and a second therapeutic agent, and uses thereof for treating cancer.
[0012] Another aspect of the disclosure provides a method of determining whether to treat a cancer patient with Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, the method comprising: (i) detecting from one or more samples from a patient, the following: ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E2F4, ERCC4, ESCO2, FAF1, FANCD2, FANCG, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, KMT2E, KPNA2, MAD2L2, MAP3K7, MLLT1 , MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1, and ZNF638; and (ii) determining, if one or more of the samples contain a genetic mutation and / or deletion, to treat the patient with a therapeutically effective amount of Compound 1 and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof; Includes.
[0013] Another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: (i) detecting from one or more samples from a patient, the following: ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E2F4, ERCC4, ESCO2, FAF1, FANCD2, FANCG, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, KMT2E, KPNA2, MAD2L2, MAP3K7, MLLT1 determining the mutation and / or deletion status of one or more genes selected from the group consisting of: , MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1 and ZNF638; and (ii) if one or more of the samples (i) contain a mutation and / or a deletion, administering to the patient a therapeutically effective amount of Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof. The present invention provides a method for treating cancer, comprising: [Brief description of the drawings]
[0014] [Figure 1] Figure 1A shows homologous recombination (HR) conversion repair. Figures 1B and 1C show that Compound 1 inhibits HR repair activity. [Diagram 2] Figure 2A shows a 53BP1 focus assay, and Figure 2B shows that Compound 1 slows the repair of radiation-induced double-strand breaks (DSBs). [Diagram 3] FIG. 3 shows that compound 1 in combination with radiation exhibits potent antitumor activity against COLO205 human colorectal adenocarcinoma xenograft tumors compared to each monotherapy alone. [Figure 4A]FIG. 4A shows that compound 1 in combination with carboplatin exhibits potent antitumor activity against PHTXS-13O human primary ovarian cancer xenografts compared to either monotherapy alone. [Figure 4B] FIG. 4B shows that compound 1 in combination with docetaxel exhibits potent antitumor activity against PHTXM-35Es human primary esophageal cancer xenografts compared to either monotherapy alone. [Figure 5A] FIG. 5A shows that compound 1 in combination with docetaxel exhibits potent antitumor activity against PHTXM-79Es human primary esophageal cancer xenografts compared to either monotherapy alone. [Figure 5B] FIG. 5B shows that compound 1 in combination with 5-FU or CPT-11 exhibited potent antitumor activity against PHTXM-79Es human primary esophageal cancer xenografts compared with each monotherapy alone. [Figure 6A] FIG. 6A shows that compound 1 in combination with gemcitabine exhibited potent antitumor activity against PHTX-249Pa human primary pancreatic xenografts compared with either monotherapy alone. [Figure 6B] FIG. 6B shows that compound 1 in combination with palbociclib exhibited potent antitumor activity against PHTXS-13O human primary ovarian cancer xenografts compared with either monotherapy alone. [Figure 7] FIG. 7 shows the in vivo anti-tumor activity of Compound 1, anti-mPD-1 antibody, anti-mPD-L1, and anti-mCTLA-4 as single agents or in combination in female BALB / c mice bearing J558 murine plasma cell tumors. [Figure 8] FIG. 8 shows the in vivo anti-tumor activity of Compound 1, anti-mPD-1 antibody, and NKTR-214 as single agents or in combination in female BALB / c mice bearing the CT26 mouse syngeneic colon tumor model. [Figure 9] FIG. 9 shows the growth inhibition curves of Compound 1 in RNASEH2A KO TK-6 cells and their counterpart parental TK-6 cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Thus, the following terms are intended to have the following meanings:
[0016] As used in this specification and the claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0017] As used herein, "administration" of a disclosed compound includes delivery of a compound as described herein, or a prodrug or other pharma- ceutically acceptable derivative thereof, to a subject, using any suitable formulation or route of administration, e.g., as described herein. As used herein, "administration" of radiation therapy, in other words, includes delivery of radiation to a subject, as is commonly understood in the field of radiation oncology.
[0018] As used herein, "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a compound or pharmaceutical composition described herein to achieve the intended use, including but not limited to disease treatment, as set forth below. In some embodiments, the amount is an amount effective to detectably kill or inhibit the growth or spread of cancer cells; the size or number of tumors; or other measures of the level, stage, progression, or severity of cancer. The therapeutically effective amount will vary depending on the intended use (in vitro or in vivo), or the subject and condition being treated, such as the subject's weight and age, the severity of the condition, the manner of administration, etc., which can be readily determined by one of ordinary skill in the art. The term also applies to a dose that induces a particular response in target cells, such as a reduction in cell migration. A particular dose will vary, for example, depending on the particular compound selected, the species of subjects and their age / existing health conditions or risk of health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, the timing of administration, the tissue to which it is administered, and the physical delivery system in which it is delivered.
[0019] As used herein, "treatment" and "treating" are used interchangeably herein and refer to an approach for obtaining beneficial or desired results, including, but not limited to, a therapeutic effect. A therapeutic effect refers to the eradication or amelioration of the underlying disorder being treated. A therapeutic effect is also achieved by the eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the patient, even though the patient may still be afflicted by the underlying disorder.
[0020] As used herein, a "subject" or "patient" to which administration is contemplated includes, but is not limited to, humans (i.e., male or female of any age) or other primates.
[0021] The terms "comprises" and "comprising" refer to "includes, but is not limited to."
[0022] The present disclosure provides a method for treating cancer in a patient in need of such treatment. The method comprises administering a therapeutically effective amount of (i) Compound 1
[0023] [ka]
[0024] and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) one or more second therapeutic agents and / or second therapies to a patient in need thereof.
[0025] The disclosure further provides therapeutic combinations comprising a therapeutically effective amount of Compound 1 and / or a tautomer or a pharma- ceutically acceptable salt or hydrate thereof, and one or more second therapeutic agents.
[0026] The disclosure further provides pharmaceutical compositions comprising a therapeutically effective amount of Compound 1 and / or a tautomer or a pharma- ceutically acceptable salt or hydrate thereof, and a second treatment method.
[0027] The disclosure further provides a pharmaceutical combination comprising a composition comprising Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and a composition comprising a second therapeutic agent, and one or more radiation treatments.
[0028] The disclosure further provides kits, including those for sale, that contain a combination comprising Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and a second therapeutic agent, each separately packaged with instructions for use to treat cancer.
[0029] The combination therapy of the present disclosure includes Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof. Compound 1 has the following structure:
[0030] [ka]
[0031] The chemical name of compound 1 is 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one. Compound 1 is a CDC7 kinase inhibitor.
[0032] CDC7 inhibitors other than Compound 1 are also expected to show good anti-tumor efficacy in the combination therapies described herein. Thus, in alternative embodiments, the present disclosure provides combination therapies further comprising a CDC7 kinase inhibitor other than Compound 1. In some embodiments, the CDC7 kinase inhibitor may be selected from LLY3143921, KC-459, MSK-777, or RXDX-103. Thus, the present disclosure also provides methods of treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a CDC7 kinase inhibitor and one or more second therapeutic agents and / or second therapies as described herein.
[0033] Also encompassed in the present disclosure are tautomers of Compound 1 or pharma- ceutically acceptable salts or hydrates of Compound 1. When Compound 1 has tautomers, each isomer is also encompassed in the present disclosure.
[0034] As used herein, phrases such as "Compound 1 and / or its tautomers" are all understood to mean Compound 1 and all its tautomers. As a non-limiting example, tautomerization can occur at the pyrazole and pyrimidine groups of Compound 1. Specific examples of tautomerization that can occur in Compound 1 include:
[0035] [ka]
[0036] Includes. Compound 1 and / or its tautomers may be used in the form of a pharma- ceutically acceptable salt. Examples of pharma-ceutically acceptable salts include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.
[0037] Compound 1 and / or its tautomers may be hydrated (e.g., hemihydrate), anhydrate, solvated, or non-solvated, all of which are encompassed by the present disclosure. In some embodiments, Compound 1 and / or its tautomers are hemihydrates.
[0038] Compound 1 and / or its tautomers or pharma- ceutically acceptable salts or hydrates or crystalline forms thereof can be obtained by the preparation methods described in, or analogous to, PCT Publication No. WO2011 / 102399, U.S. Pat. No. 8,722,660, U.S. Pat. No. 8,921,354, U.S. Pat. No. 8,933,069, and U.S. Patent Application Publication No. 2015 / 158882, which are incorporated herein by reference in their entireties and for all purposes.
[0039] Compound 1 and / or its tautomers or pharma- ceutically acceptable salts or hydrates thereof may be in the form of crystals (e.g., crystalline form A, crystalline form I, etc.), and the crystalline forms of the crystals may be single or multiple, both of which are encompassed by Compound 1. The crystals may be in any form and may be prepared by the methods described in PCT Publication No. WO2017 / 172565, published October 5, 2017, which is incorporated by reference in its entirety for all purposes. In some embodiments, Compound 1 and / or its tautomers or its pharma- ceutically acceptable salts or hydrates thereof may be in the form of crystalline form I as described in WO2017 / 172565. In some embodiments, Compound 1 and / or its tautomer or a pharma- ceutically acceptable salt or hydrate is a crystalline form of a hemihydrate of Compound 1 (i.e., a hemihydrate of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one). For example, Compound 1 and / or its tautomer or a pharma- ceutically acceptable salt or hydrate can be a crystalline form I of a hemihydrate of Compound 1.
[0040] The combination therapy of the present disclosure includes administration of a second therapeutic agent and / or a second treatment. In some embodiments, the second treatment is radiation treatment. In some embodiments, the second therapeutic agent is selected from a DNA damaging agent, a tubulin binding agent, a cell signaling modulator, an HSP90 inhibitor, an HDAC inhibitor, a checkpoint inhibitor, an antimetabolite, etoposide, entinostat, obatoclax, and tunicamycin.
[0041] In some embodiments, the combination therapy includes a third agent, hi some embodiments, the third agent is a therapeutic agent selected from among the second therapeutic agents described herein.
[0042] In some embodiments, the second therapeutic agent is an agent that has a synergistic effect when used in combination therapy with Compound 1 and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof. For example, in some embodiments, the second therapeutic agent is a compound or class of compounds reported herein to produce a synergistic effect when used in combination therapy with Compound 1 and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof.
[0043] In some embodiments, the second therapeutic agent is a DNA damaging agent. In some embodiments, the DNA damaging agent is selected from the group consisting of mitomycin C, teniposide, topotecan hydrochloride, carboplatin, decitabine, melphalan, mitoxantrone hydrochloride, irinotecan, cisplatin, oxaliplatin, bleomycin, busulfan, cytarabine, daunorubicin, thiotepa, doxorubicin hydrochloride, gemcitabine, 8-methoxypsoralen, aphidicolin glycinate, brefeldin A, carmustine, chlorambucil, dacarbazine, dactinomycin, mercaptopurine, O6-benzylguanine, SN-38, temozolomide, and 5-FU (fluorouracil).
[0044] In some embodiments, the DNA damaging agent is selected from the group consisting of myitomycin C, teniposide, topotecan, carboplatin, decitabine, melphalan, mitoxantro HCl, irinotecan, cisplatin, oxalitplatin, and bleomycin.
[0045] In some embodiments, the DNA damaging agent is selected from the group consisting of myitomycin C, teniposide, topotecan, carboplatin, decitabine, and melphalan.
[0046] In some embodiments, the DNA damaging agent is selected from the group consisting of topotecan, irinotecan, carboplatin, cisplatin, oxaliplatin, and gemcitabine.
[0047] In some embodiments, the DNA damaging agent is selected from the group consisting of carboplatin, 5-FU, irinotecan, and gemcitabine.
[0048] In some embodiments, the DNA damaging agent is selected from the group consisting of 5-FU, irinotecan, and gemcitabine.
[0049] In some embodiments, the DNA damaging agent is a topoisomerase inhibitor or a platinum compound.
[0050] In some embodiments, the second therapeutic agent is a tubulin binding agent. In some embodiments, the tubulin binding agent is selected from docetaxel, paclitaxel, vincristine sulfate, and colsemid. In some embodiments, the tubulin binding agent is docetaxel.
[0051] In some embodiments, the second therapeutic agent is a cell signaling modulator. In some embodiments, the cell signaling modulator is selected from the group consisting of alvocidib, BEZ-235, BKM-120, flavopiridol, GDC-0941, PKC412, PLX4032, afatinib, osimertinib, poziotinib, lapatinib, trametinib, cobinetinib, binimrtinib, binimrtinib, selumetinib, palbociclib, ribociclib, roscovitine, mirciclib, dinaciclib, flavopiridol, PHA-793887, AZD5438 , BS-181, PF-06873600, KU-55933, KU-60019, VE-821, VE-822, AZD6738, wortmannin, AZD1390, LY2090314, CHI-99021, pictilicib, idelalisib, bupalisib, PI-103, KU-57788, alpelisib, voxtalisib, omipalisib, PF-04691502, AZD6482, GSK1059615, duvelisib, gedatolisib, copanlisib, taselisib, AMG319, seretalisib, piralalisib, voxtalisib, selavelisib and nemiralisib.
[0052] In some embodiments, the cell signaling modulator is selected from GDC-0941, BKM-120, alvocidib, BEZ-235, flavopiridol, PKC412, PLX4032, and palbociclib. In some embodiments, the cell signaling modulator is GDC-0941.
[0053] In some embodiments, the second therapeutic agent is an HSP90 inhibitor, hi some embodiments, the HSP90 inhibitor is selected from 17-AAG, 17-DMAG, and AUY-922.
[0054] In some embodiments, the second therapeutic agent is an HDAC inhibitor. In some embodiments, the HDAC inhibitor is selected from entinostat and panobinostat. In some embodiments, the HDAC inhibitor is entinostat.
[0055] In some embodiments, the second therapeutic agent is a checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is selected from an anti-PD-1 antibody, NKTR-214, an anti-CTLA-4 antibody, and an anti-PD-L1 antibody. In some embodiments, NKTR-214 and an anti-PD-1 antibody are used as the second and third therapeutic agents.
[0056] In some embodiments, the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, cemiplimab, and spartalizumab. In some embodiments, the anti-CTLA-4 antibody is selected from ipilimumab and tremelizumab. In some embodiments, the anti-PD-L1 antibody is selected from atezolizumab, durvalumab, and avelumab.
[0057] In some embodiments, the second therapeutic agent is etoposide. In some embodiments, the second therapeutic agent is entinostat. In some embodiments, the second therapeutic agent is obatoclax. In some embodiments, the second therapeutic agent is tunicamycin. In some embodiments, the second therapeutic agent is AT101. In some embodiments, the second therapeutic agent is azacytidine. In some embodiments, the second therapeutic agent is bafilomycin A. In some embodiments, the second therapeutic agent is thapsigargin.
[0058] In some embodiments, the second or third therapeutic agent is selected from the group consisting of ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E2F4, ERCC4, ESCO2, FAF1, FANCD2, FANCG, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, KMT2E, KPNA2, MAD2L2, One or more substances that inhibit the gene function of MAP3K7, MLLT1, MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1 or ZNF638.
[0059] In some embodiments, substances that inhibit gene function include (i) inhibitors of gene expression (e.g., antisense RNA, siRNA, shRNA) and (ii) inhibitors of proteins translated from genes (e.g., small molecule compounds, antibodies).
[0060] In some embodiments, the disclosure provides a method for predicting the likelihood that a patient will therapeutically respond to a cancer treatment comprising administration of Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, the method comprising predicting the likelihood that a patient will therapeutically respond to a cancer treatment comprising administering Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, the method comprising predicting the likelihood that a patient will therapeutically respond to a cancer treatment comprising administering Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, the method comprising predicting the likelihood that a patient will therapeutically respond to a cancer treatment , KMT2E, KPNA2, MAD2L2, MAP3K7, MLLT1, MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1 and ZNF638.
[0061] In some embodiments, the gene is selected from the group consisting of RNASEH2A, RNASEH2B and RNASEH2C. In some embodiments, the gene is RNASEH2B.
[0062] In one embodiment, the disclosed method includes (1) determining mutation and / or deletion status, and (2) predicting that the patient will have an improved likelihood of therapeutically responding to the cancer treatment based on the status of step (1), specifically, predicting that the patient will have an improved likelihood of therapeutically responding to the cancer treatment if testing of the sample reveals that one or more genes are mutated and / or deleted.
[0063] In one embodiment, the disclosure provides a method for determining whether a patient has one or more mutations and / or deletions in a gene that is a target of the present invention, comprising: (1) (a) obtaining or having obtained a biological sample from a patient; and (b) performing or having performed an assay on the biological sample to determine whether the patient has one or more mutations and / or deletions in a gene that is a target of the present invention. (2) determining whether the patient has a mutation and / or deletion condition by a method comprising administering to the patient a therapeutically effective amount of Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof if the patient has a mutation and / or deletion condition, wherein the mutation and / or deletion gene is selected from the group consisting of ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E2F4, ERCC4, ESCO2, FAF1, FANCD2, FANC G, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, KMT2E, KPNA2, MAD2L2, MAP3K7, MLLT1, MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1, and ZNF638. In some embodiments, the method further comprises a second therapeutic agent, e.g., a DNA damaging agent.
[0064] The method, assay or test for determining mutation and / or deletion status is well known in the art.Examples of such methods include but are not limited to RFLP (restriction fragment length polymorphism), PCR-SSCP (single-stranded DNA conformation polymorphism), ASO (allele-specific oligonucleotide) hybridization, sequencing, ARMS (amplification refracting mutation system), denaturing gradient gel electrophoresis, RNAse A cleavage, DOL (dye-labeled oligonucleotide ligation), TaqMan PCR, primer extension, Invader, Scorpion-ARMS, F-PHFA, pyrosequencing, BEAMing, RT-PCR, FISH, IHC, immunodetection, Western blot, ELISA, radioimmunoassay, immunoprecipitation, FACS, HPLC, surface plasmon resonance, optical spectroscopy and mass spectrometry. In particular, next generation sequencing methods, such as whole exome sequencing (WES) and RNA sequencing (RNASeq), can be used.
[0065] Examples of biological samples used in the methods, assays or tests include, but are not limited to, serum, whole fresh blood, peripheral blood mononuclear cells, frozen whole blood, fresh plasma, frozen plasma, urine, saliva, skin, hair follicles, bone marrow, tumor tissue, tumor biopsy, or archived paraffin-embedded tumor tissue. The sample is preferably a tumor tissue or tumor biopsy containing cancer cells.
[0066] The mutational status of a gene can be, for example, at the level of the genomic DNA, protein and / or mRNA transcript of the gene. Preferably, the presence or absence of a mutation in a gene is determined at the level of the genomic DNA or mRNA transcript.
[0067] In some embodiments, the combination therapy of the present disclosure may include one or more radiation treatments. For example, the combination therapy of the present disclosure may include administration of compound 1 and / or its tautomer or its pharma- ceutically acceptable salt or hydrate, and one or more radiation treatments. Radiation therapy for treating cancer is well known in the art. See, for example, Principles and Practice of Radiation Therapy, Washington and Leaver, 4th Edition, 2015. Example 4 in the Examples section below describes the treatment of mice bearing colorectal xenograft tumors irradiated daily with a dose of 3 Gy using an X-ray irradiator. The results show the effectiveness of radiation therapy in combination with the treatment of compound 1.
[0068] In some embodiments, compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and the second therapeutic agent may be formulated as a pharmaceutical composition containing a pharma- ceutically acceptable carrier or diluent, as well as any other known adjuvants and excipients, according to conventional techniques, such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1995.
[0069] Pharmaceutical compositions used in embodiments of the present disclosure may also include diluents, fillers, salts, buffers, detergents (e.g., non-ionic detergents such as Tween-80), stabilizers (e.g., sugars or protein-free amino acids), preservatives, tissue fixatives, solubilizing agents, and / or other materials suitable for inclusion in a pharmaceutical composition.
[0070] The compounds used in the embodiments of the present disclosure may be administered via any suitable route, such as oral, nasal, inhalable, topical (including buccal, transdermal and sublingual), rectal, vaginal and / or parenteral routes.
[0071] In some embodiments, one or more compounds used in the present disclosure are administered orally, for example, with an inert diluent or an assimilable edible carrier. The active ingredient can be enclosed in a hard or soft shell gelatin capsule or compressed into tablets. Pharmaceutical compositions suitable for oral administration include ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, containing such carriers as are known in the art to be suitable.
[0072] In some embodiments, one or more compounds used in the present disclosure are administered parenterally. As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include epithelial, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural, and intrasternal injection and infusion.
[0073] The disclosed method provides effective treatment for cancer patients. In some embodiments, the cancer treated with the disclosed combination therapy is a cancer mediated by CDC7 (e.g., colorectal cancer (e.g., metastatic colorectal cancer), lung cancer (e.g., non-small cell lung cancer (e.g., squamous non-small cell lung cancer (including locally advanced squamous non-small cell lung cancer and metastatic squamous non-small cell lung cancer)), mesothelioma, pancreatic cancer (e.g., metastatic pancreatic cancer), pharyngeal cancer, laryngeal cancer, esophageal cancer (e.g., squamous esophageal cancer), gastric cancer, duodenal cancer, small intestine cancer, breast cancer, ovarian cancer, testicular cancer, prostate cancer, liver cancer, thyroid cancer, kidney cancer, uterine cancer, brain tumor, retinoblastoma, skin cancer, bone tumor, bladder cancer, blood cancer (e.g., multiple myeloma, leukemia, malignant lymphoma, Hodgkin's disease, chronic myeloproliferative disease).
[0074] In some embodiments, the cancer treated with the combination therapy of this disclosure is selected from the group consisting of lung cancer (e.g., non-small cell lung cancer (e.g., squamous non-small cell lung cancer, including locally advanced squamous non-small cell lung cancer and metastatic squamous non-small cell lung cancer)), colorectal cancer (e.g., metastatic colorectal cancer), ovarian cancer, pancreatic cancer (e.g., metastatic pancreatic cancer), esophageal cancer, prostate cancer, breast cancer, plasmacytoma, hepatocellular carcinoma, melanoma, and lymphoma. In some embodiments, the cancer is selected from lung cancer (e.g., non-small cell lung cancer (e.g., squamous non-small cell lung cancer, including locally advanced squamous non-small cell lung cancer and metastatic squamous non-small cell lung cancer)), colorectal cancer (e.g., metastatic colorectal cancer), ovarian cancer, and pancreatic cancer (e.g., metastatic pancreatic cancer).
[0075] In some embodiments, the cancer treated with the combination therapy of this disclosure is a cancer that is resistant to platinum compounds.
[0076] In some embodiments, the cancer that is treated by the combination therapy of this disclosure is a type of cancer that can repair homologous recombination in cancer cells.Cancer that can repair homologous recombination means that the cancer is not HRD (homologous recombination deficient).One example of HRD cancer is BRCA mutation cancer.There are commercially available kits to test cancer for HRD. One method involves measuring from a biological sample from the patient the expression level of one or more human genes involved in the repair of double stranded DNA breaks, where the biological sample is a tumor cell or tissue from the patient and the one or more human genes comprise two or more genes selected from the group consisting of RPA, ATRIP, ATR, Mre11 / Rad50 / ΝΒS1, ATM, MDC1, BRCA1, 53ΒΡ1, CtIP, Rifl, ku70, ku80, Artemis, DNA-pk, XRCC4 / ligase IV, Rad 51, Palb2, BRCA2, RAD52, XRCC3 / RAD51C, XRCC2 / RAD51B / RAD51D, RAD51AP1, BLM, PAR, RAD54L, RAD54B, Fbhl, WRN, MYC, and STAT3. See, for example, US2016 / 0369353A1, which is incorporated herein by reference.
[0077] In some embodiments, the dose strength of Compound 1 and / or its tautomer or its pharma- ceutically acceptable salt or hydrate ranges from 5 to 200 mg. For example, in some embodiments, the medicament comprises a dose strength of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 mg of Compound 1 and / or its tautomer or its pharma- ceutically acceptable salt or hydrate. In some embodiments, the daily dose of Compound 1 and / or its tautomer or its pharma- ceutically acceptable salt or hydrate administered to an adult (body weight about 60 kg) ranges from 10 to 200 mg. In other embodiments, the daily dose of Compound 1 and / or its tautomer or its pharma- ceutically acceptable salt or hydrate administered to an adult is about 1 to 1000 mg, about 3 to 300 mg, or about 10 to 200 mg, which can be given in a single dose or two or three doses per day. In some embodiments, Compound 1 and / or its tautomer or its pharma- ceutically acceptable salt or hydrate is administered orally.
[0078] In some embodiments, the combination therapy includes topotecan, where topotecan is at about 0.1 to about 10 mg / m 2 (For example, about 0.5 to about 2 mg / m 2 or about 1.5 mg / m 2 or about 0.75 mg / m 2 ) is administered intravenously.
[0079] In some embodiments, the combination therapy includes carboplatin, where the carboplatin is at about 50 mg / m 2 ~about 1000mg / m 2 (For example, about 100 to about 500 mg / m 2 , or about 300 mg / m 2 ) is administered intravenously.
[0080] In some embodiments, the combination therapy includes gemcitabine, where gemcitabine is at about 100 to about 5000 mg / m 2 (For example, about 500 to about 2000 mg / m 2 , or about 1000 mg / m 2 ) is administered intravenously.
[0081] In some embodiments, the combination therapy includes irinotecan, where irinotecan is at about 10 mg / m 2 ~about 500mg / m 2 (For example, about 50 to about 300 mg / m 2 , or about 125 mg / m 2 or about 180 mg / m 2 ) is administered intravenously.
[0082] In some embodiments, Compound 1 and / or its tautomer or a pharma- ceutically acceptable salt or hydrate thereof is administered daily, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, or once every four weeks.
[0083] In some embodiments, Compound 1 and / or a tautomer or a pharma- ceutically acceptable salt or hydrate thereof, and the second therapy may be administered simultaneously or sequentially in any order, hi some embodiments, they may be administered separately or together in one or more pharmaceutical compositions.
[0084] In some embodiments, Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) administration of a second therapeutic agent to a cancer patient.
[0085] In some embodiments, the combination therapy comprises a 14-day cycle in which compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof is administered once daily on days 1-14, and radiation treatment is administered on days 1, 2, 3, 8, 9, and 10.
[0086] In some embodiments, the combination therapy comprises a 28 day cycle in which compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof is administered once daily on days 1-28 and topotecan is administered on days 1-5 and 15-19.
[0087] In some embodiments, the combination therapy comprises a 28-day cycle in which compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof is administered once daily on days 1 through 28, and carboplatin is administered on days 1, 5, 9, 13, 17, 21, and 25 (i.e., every 4 days).
[0088] In some embodiments, the combination therapy comprises a 14-day cycle in which compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof is administered once daily on days 1-14, and carboplatin is administered on days 1, 5, 9, and 13 (i.e., every 4 days).
[0089] In some embodiments, the combination therapy comprises a 21-day cycle in which compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof is administered once daily on days 1 through 21, and gemcitabine is administered on days 1, 4, 8, 11, 15, and 18 (i.e., twice a week).
[0090] In some embodiments, the combination therapy comprises a 21-day cycle in which compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof is administered once daily on days 1 through 21, and irinotecan is administered on days 1, 5, 9, 13, 17, and 21 (i.e., every 4 days).
[0091] Disclosed herein, in some embodiments, is a method of treating colorectal cancer in a patient in need thereof, comprising administering a therapeutically effective amount of (i) Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) one or more radiation treatments.
[0092] Disclosed herein, in some embodiments, is a method of treating ovarian cancer in a patient in need thereof, comprising administering therapeutically effective amounts of (i) Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) carboplatin.
[0093] Disclosed herein, in some embodiments, is a method of treating esophageal cancer in a patient in need thereof, comprising administering therapeutically effective amounts of (i) Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) docetaxel.
[0094] Disclosed herein, in some embodiments, is a method of treating esophageal cancer in a patient in need thereof, comprising administering therapeutically effective amounts of (i) Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) 5-FU or CPT-11.
[0095] Disclosed herein, in some embodiments, is a method of treating pancreatic cancer in a patient in need thereof, comprising administering therapeutically effective amounts of (i) Compound 1 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) gemcitabine.
[0096] Disclosed herein, in some embodiments, is a method of treating plasmacytoma in a patient in need thereof, comprising administering a therapeutically effective amount of (i) Compound 1 and / or a tautomer thereof, or a pharma- ceutically acceptable salt or hydrate thereof, and (ii) an anti-mPD-1 antibody, an anti-mPD-L1 antibody, or an anti-mCTLA-4 antibody.
[0097] Disclosed herein, in some embodiments, is a method of treating colon cancer in a patient in need thereof, comprising administering a therapeutically effective amount of (i) Compound 1, and / or a tautomer thereof, or a pharma-ceutically acceptable salt or hydrate thereof, and (ii) an anti-mPD-1 antibody and / or NKTR-214. EXAMPLES
[0098] Example 1: In vitro studies To identify agents that enhance the antiproliferative activity of compound 1, in vitro combination studies of various agents with compound 1 were performed in COLO205, A549, SW620, SW48, H460, and HCT116 cancer cells using a fully automated system for assay execution and data analysis. Adenosine 5'-triphosphate (ATP) was used as a measure of cell viability, and combinations with compound 1 were classified as synergistic, additive, sub-additive, or antagonistic based on their antiproliferative effects. Combination performance was ranked based on the most frequently occurring synergistic effects in the six cell lines tested.
[0099] A stock solution of Compound 1 was prepared in dimethyl sulfoxide (DMSO). Serially diluted stock solutions (0.003-200 μM) were stored at approximately 4°C.
[0100] The cell lines used in Example 1 are listed in Table 1.
[0101] [Table 1]
[0102] Each combination pair was evaluated in individual 384-well plates containing variable doses of both compounds as single agents, and in two 10x10 matrices (duplicates) containing a mixture of the two test compounds. Briefly, compounds were added to the cell test plates 16 hours after cell plating, and then viability was assessed 72 hours later. Continuous cultures of tumor cells were maintained under standard cell culture conditions (i.e., in a humidified chamber set at 37°C with a 5% carbon dioxide atmosphere). After cell counting, cells were plated into the assay plates in 25 μL of cell culture medium. 72 hours after compound addition, ATP levels were measured to assess cell viability. Plating density was selected to ensure optimal linear growth over 72 hours.
[0103] Compound dilution and compound delivery to the assay plate were performed using Echo TM The assay was performed on a HighRes Robotic System (HighRes Biosolutions, Woburn, MA, USA) equipped with a Liquid Handler (Labcyte, Sunnyvale, CA, USA). First, 384-well low dead volume (LDV) plates containing DMSO (Appendix B) and 10 mM compound stock solutions were used to generate dilution plates of the required intermediate compounds. These were then used for compound transfer to the cell assay plates. All wells were backfilled and given a fixed percentage of DMSO.
[0104] Final DMSO concentrations were kept constant in all wells across the plate and maintained below 0.5%. Preliminary studies indicate that 0.5% DMSO has no discernible difference in proliferation rate compared to cells grown without DMSO. Dose concentrations of each targeted agent ranged from inactive to maximally effective (defined as causing maximum growth inhibition). These cell viability data sets were used to determine 50% efficacy (EC 50 The single agent concentrations that yielded ΔP values were calculated to classify the inhibitor combination response. Cells treated with vehicle (DMSO) in two rows, or serial dilutions of single compounds in one plate row / column, served as untreated and single compound controls, respectively.
[0105] Cell Titer-Glo® Cell Proliferation Assay Compound activity in A549, COLO205, H460, HCT116, SW48, and SW620 cancer cell lines was assessed using Cell Titer-Glo® (Promega, Madison, WI, USA). After 72 h of incubation, plates were processed according to the package insert protocol for the Promega Luminescence ATP Detection System. Briefly, 25 μL of cell lysis / substrate solution (provided in kit form) was added to each well and plates were incubated for 10 min at room temperature. Luminescence was measured using a PHERAstar multilabel counter (BMG Labtech, Ortenberg, Germany) or a LEADseeker (GE Healthcare Life Sciences, Piscataway, NJ, USA).
[0106] Data Analysis ATPlite TM Cell proliferation assay Analyze the luminescence values and determine EC 50 Curves were generated and synergy assessed. Data reader files were uploaded along with an automated work file defining plate and well contents. % activity was calculated for each well relative to plate control.
[0107] statistics Each plate corresponding to a single agent combination was analyzed separately. First, viability measurements were normalized by scaling the data so that the median of the negative controls was 0 and the median of the positive controls was 100. Some wells on a plate contained only one agent, and this data was used to derive the EC of the single agent by fitting the data to the Hill equation. 50 was calculated.
[0108] In the combined analysis, a response surface model was used to describe the relationship between normalized survival and drug concentration. The data were fitted to the model by minimizing the sum of squares of the residuals. Based on the fitted response surface, plots of constant survival, called isobolograms, were generated.
[0109] Combination Index and Nonlinear Blending were used as measures of drug synergy. To calculate the Combination Index, a 50% isobologram (dose contour with 50% survival) was used. Standard errors were used for both of these measures using the Cramer-Rao lower bound. A standard procedure was created to generate calls to characterize the survival effect of each combination (synergy, additivity, subadditivity, or antagonism). If a combination index was present, these measures were used to create the call. If a combination index was not present because one or both or the compounds did not achieve a 50% reduction in survival, a similar procedure based on nonlinear blending was used to create the call. Tables 2 and 3 show how these calls were created.
[0110] [Table 2]
[0111] [Table 3]
[0112] Table 4 shows the results of the antiproliferative activity of the combinations of Compound 1 and DNA damaging agents tested. These studies revealed that in combination with Compound 1, DNA damaging agents such as topoisomerase inhibitors and platinum compounds were most likely to produce synergistic antiproliferative effects.
[0113] [Table 4]
[0114] Table 4: Combinations are ordered based on the occurrence of synergy in multiple cell lines. All experiments labeled inconclusive or inconclusive were repeated at least twice. Inconclusive refers to low data quality, likely specific to the particular cell line or compound used. Inconclusive refers to the inability to make a call based on statistical criteria. Combination results with "---" were not performed in this study.
[0115] Table 5 shows the results of the antiproliferative activity of the tested combinations of Compound 1 with tubulin binding agents, etc. These studies revealed that in combination with Compound 1, these agents exhibit synergistic or additive antiproliferative effects, etc. under certain conditions.
[0116] [Table 5]
[0117] Example 2: In vitro studies of selected compounds, additional cell lines The in vitro antiproliferative effects of selected compounds were tested in additional cell lines, including ovarian cancer (SKOV3) and pancreatic cancer (MIA-PACA-2) cell lines. The study revealed that topoisomerase inhibitors and DNA crosslinkers induced additive or synergistic effects with Compound 1 in several cancer cell lines. The results are shown in Table 6.
[0118] [Table 6]
[0119] Example 3A: Compound 1 inhibits homologous recombination (HR) repair activity The efficiency of homologous recombination (HR) was assessed using an I-SceI expression plasmid (I-SceI) and an I-SceI repair reporter plasmid (DR-GFP) composed of two different mutant GFP genes, one of which contains a unique I-SceI restriction site (Figure 1A). The assay works through gene conversion repair of the double-strand break caused by I-SceI digestion. The DR-GFP plasmid repaired by homologous recombination expresses GFP. Human embryonic kidney 293T cells were transfected with either 5 μg of DR-GFP plus 10 μg of I-SceI in the presence (300 nM) or absence of compound 1. 72 hours after transfection, cells were fixed with 4% paraformaldehyde for 20 min at room temperature and the number of GFP-expressing cells was assessed by flow cytometry (Figures 1B and 1C). These results indicate that compound 1 inhibits HR repair activity.
[0120] Example 3B: Compound 1 Delays Repair of Radiation (IR)-Induced DNA Double-Strand Breaks (DSBs) Human cervical adenocarcinoma HeLa cells were treated with or without compound 1 at 300 nM, followed by 4 Gy irradiation (IR) treatment using an X-ray irradiator (MBR-1520R-3, Hitachi Power Solutions Co., Ltd., Ibaraki, Japan). 8 or 48 h after IR treatment, cells were fixed with 4% paraformaldehyde for the following immunofluorescence experiments. 53BP1 foci formation was used as an indicator of IR-induced DSBs. After permeabilization, cells were incubated with anti-53BP1 antibody (2 μg / ml) for 60 min at 37 °C, and then incubated with Alexa-594-labeled secondary antibody for 30 min at 37 °C. Images were taken with an Axiovert 200M microscope (Carl Zeiss).
[0121] In cells treated with IR alone, 53BP1 foci positive cells (≧10 foci / cell) dramatically increased 8 hours after IR treatment, but the foci positive cells decreased to a level comparable to that of untreated cells, indicating that DNA repair was completed 48 hours after IR treatment (FIGS. 2A and 2B). In contrast, in cells co-treated with IR and Compound 1, 53BP1 foci positive cells were frequently observed 48 hours after IR treatment. These data suggest that Compound 1 delays the repair of IR-induced DSBs (FIG. 2B).
[0122] Based on the results of Examples 2A and 2B, it was hypothesized that the combination of Compound 1 and a DNA damaging agent may act synergistically to treat cancer.
[0123] Example 4: In vivo antitumor activity of Compound 1 and radiation as single agents and in combination in nude mice bearing COLO205 human colorectal adenocarcinoma xenografts A human colorectal cancer cell line, COLO205 xenograft model was established by subcutaneous injection of a cell suspension (5 × 10 6 Cells / 100 μl / site, Hanks' balanced salts and BD matrigel TM matrix (BD biosciences) in a 1:1 mixture. 3 Mice were randomly assigned to treatment groups on the day before the start of treatment (day 0). Compound 1 was suspended in 0.5 w / v% methylcellulose and orally administered to mice at a dose of 40 mg / kg once a day on days 1 to 14. Mice in the irradiation group were irradiated with a dose of 3 Gy on days 1, 2, 3, 8, 9, and 10 under pentobarbital anesthesia. Tumors on the flanks of mice were irradiated using an X-ray irradiator (MBR-1520R-3, Hitachi Power Solutions Co., Ltd., Ibaraki), and the non-tumor parts of the mice were shielded with a lead plate. Tumor size was measured with a caliper, and tumor volume was calculated using the formula V = (LW 2) / 2, where L and W are the length and width of the tumor, respectively, and reported in cubic millimeters (FIG. 3). The results of this study show that compound 1 in combination with irradiation exhibited strong antitumor activity and improved antitumor efficacy against COLO205 human colorectal adenocarcinoma xenograft tumors compared to each monotherapy alone.
[0124] Example 5: In vivo antitumor activity of Compound 1 in combination with other agents in cell-derived xenograft (CDX), patient-derived xenograft (PDX) and syngeneic mouse tumor syngraft models To investigate the in vivo antitumor activity of Compound 1 in combination with other drugs, studies were conducted using cell-derived xenograft (CDX), patient-derived xenograft (PDX) and syngeneic mouse tumor syngeneic models. As shown in Table 7, cells or patient-derived tumors were inoculated in one of two ways (Methods A and B): Method A; cells were maintained by subcutaneous inoculation of tumor cells at various concentrations in respected mice, either immunodeficient nude mice or immunocompetent mice. Method B: Patient-derived tumors were maintained in nude mice by subcutaneous inoculation of tumor pieces (approximately 2 × 2 × 2 mm). For syngeneic mouse studies, tumor pieces (approximately 50 mm) were inoculated into nude mice. 3 (For example, 40 to 75 mm 3 ) or 200 mm for xenograft studies. 3 (For example, 110~270mm 3 Mice bearing tumors measuring 0.01 mm or 0.1 mm in size were randomly assigned to treatment groups the day before treatment began (day 0).
[0125] Compound 1 (crystal form I) was suspended in 0.5 w / v% methylcellulose and orally administered to mice. The antibodies administered in the experiment are listed in Table 8. Concomitant medications were administered as shown in Table 9.
[0126] Tumor size was measured with a caliper and tumor volume was calculated using the formula V = (LW 2) / 2, where L and W are the length and width of the tumor, respectively, and reported in cubic millimeters.
[0127] Statistical analysis of the combination effect on tumor growth was performed as follows: All tumor values (tumor volume or photon flux) are log 10 A value of 1 was added before transformation. These values were compared between treatment groups to assess whether differences in trends over time were statistically significant. To compare pairs of treatment groups, the following mixed-effects linear regression model was fitted to the data using maximum likelihood methods:
[0128]
number
[0129] Here, Y ijk is the log 10 is the tumor value, and Y i0k is the logarithm of day 0 (baseline) of the kth animal in the ith treatment 10 Tumor values, days j is the time point in the middle of the median (day 2 j (along with e) are treated as continuous variables. ijk is the residual error. A spatial power law covariance matrix was used to account for repeated measurements over time in the same animal. Interaction terms and days 2 j Terms were deleted if they were not statistically significant.
[0130] A likelihood ratio test was used to assess whether a given pair of treatment groups showed a statistically significant difference. The -2 log likelihood of the full model was compared to that without the treatment term (reduced model) and the difference in values was tested using a chi-square test. The degrees of freedom for the test were calculated as the difference between the degrees of freedom of the full model and the reduced model. The expected difference in log tumor values (Y ijk -Y i0k , this is log 10(which can be interpreted as fold change from day 0) was obtained from the above model to calculate the mean AUC value for each treatment group. dAUC values were then calculated as:
[0131]
number
[0132] This is the AUC ctl is assumed to be positive. AUC ctl If is negative, the above formula is multiplied by -1.
[0133] For synergy analysis, the observed difference in log tumor values was used to calculate the AUC value for each animal. If an animal in a treatment group was removed from the study, the last observed tumor value was carried forward to all subsequent time points. The AUC for the control or vehicle group was calculated using the predicted values from the pairwise model described above. We defined a measure of synergy as follows:
[0134]
number
[0135] Here, A k and B. k is the kth animal in each treatment group, and AB k is the kth animal in the combination treatment group. AUC ctl is the model predicted AUC for the control group and was treated as a constant with no variation. The standard error of the synergy score was calculated as the square root of the sum of the squared standard errors across groups A, B, and AB. The degrees of freedom were estimated using the Welch-Satterthwaite equation. Hypothesis tests were performed to determine whether the synergy score was different from 0. P values were calculated by dividing the synergy score by its standard error and tested against a t-distribution (two-tailed) with the degrees of freedom calculated above.
[0136] Effects were classified into four different categories. A synergy score less than zero was considered synergistic, whereas a synergy score not statistically different from zero was considered additive. A combination was subadditive if the synergy score was greater than zero but the mean AUC of the combination was lower than the lowest mean AUC of the two monotherapies. A combination was antagonistic if the synergy score was greater than zero and the mean AUC of the combination was greater than the mean AUC of at least one of the monotherapies.
[0137] When necessary, interval analyses included a particular treatment group and time interval compared to another treatment group and time interval. For a given group, time interval, and animal, the daily tumor growth rate was
[0138]
number
[0139] where ΔY is the log 10 where p is the difference in tumor volume and Δt is the length of the time interval. If one or both time points were missing, the animal was ignored. The mean rates across animals were then compared using a two-tailed unpaired t-test with unequal variances.
[0140] Given the exploratory nature of this study, there were no prespecified adjustments for multiple comparisons and the endpoints examined. In this analysis, all P values <0.05 were considered statistically significant. The results of this study are shown in Table 9.
[0141] [Table 7]
[0142] [Table 8]
[0143] [Table 9-1]
[0144] [Table 9-2]
[0145] [Table 9-3]
[0146] [Table 9-4]
[0147] [Table 9-5]
[0148] [Table 9-6]
[0149] [Table 9-7]
[0150] [Table 9-8]
[0151] Example 6 To discover genes that may be sensitive to treatment with compound 1, a CRISPR-Cas9 knockout screen was performed at Horizon Discovery Ltd (Cambridge, UK). Twelve cancer cell lines (A549, BxPC3, Calu-1, COLO205, KYSE140, KYSE150, KYSE520, KYSE70, MIA PaCa-2, NCI-H292, PANC1, and RKO) and a custom gRNA library for 1969 genes were used for the screen.
[0152] Cells were treated with lentivirus containing gRNA and Cas-9 for 2 hours, and then the cells were resuspended in fresh medium. After a 48-hour recovery period, puromycin was added to select the cells. After completion of selection, cells were maintained in medium containing DMSO, low dose of compound 1, or high dose of compound 1. The dose of compound 1 was adjusted at each passage to maintain appropriate selection pressure. After 12 population doublings of DMSO-treated cells, cells were harvested and stored in a deep freezer. Genomic DNA of the cells was extracted. Samples were prepared and purified using the Illumina NextSeq next-generation sequencing (NGS) platform for amplicon sequencing. Analysis of the NGS dataset was performed using Horizon data processing scripts. The following formula was used to analyze the data and calculate the enrichment score of each gene and its P-value:
[0153] Enrichment score (ES) = log2(compound 1 + guide i) + log2(control + dummy guide) - log2(compound 1 + dummy guide) - log2(control + guide i)
[0154] Genes with ES<0 and P value<0.05 were defined as sensitivity hit genes in comparison between control (DMSO-treated) cells and cells treated with low dose of Compound 1. The following genes were identified as sensitivity hit genes in more than three cancer cell lines; ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E 2F4, ERCC4, ESCO2, FAF1, FANCD2, FANCG, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, KMT2E, KPNA2, MAD2L 2, MAP3K7, MLLT1, MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH 2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1, ZNF638.
[0155] This experiment revealed that genetic mutation or deletion of at least one of the hit genes rendered cancer cells more sensitive to Compound 1.
[0156] Example 7 To further determine whether RNASEH2A is involved in the sensitivity to compound 1, an in vitro growth inhibition assay of compound 1 was performed in RNASEH2A knockout (KO) TK-6 cells and their counterpart parental TK-6 cells. RNASEH2A KO TK-6 cells and their counterpart parental TK-6 cells were obtained from Kyoto University under a material transfer agreement. The cell lines were cultured in RPMI-1640 medium (Fujifilm Wako Pure Chemical Industries, Ltd., Osaka, Japan) supplied with 10% fetal bovine serum (CORNING Inc., NY, USA), sodium pyruvate (Fujifilm Wako Pure Chemical Industries, Ltd., Osaka, Japan) and penicillin-streptomycin (Fujifilm Wako Pure Chemical Industries, Ltd., Osaka, Japan). A stock solution of compound 1 was prepared in dimethyl sulfoxide (DMSO) and stored at approximately -20 °C.
[0157] Cell proliferation was measured using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega, WI, USA). The CellTiter-Glo Luminescent Cell Viability Assay is a homogenous method to determine the number of viable cells in culture based on the quantification of ATP present, which indicates the presence of metabolically active cells. Compound 1 was diluted and the solution was plated at 20 μL / well in a 384-well plate. 20 μL of cells in medium were then seeded and adjusted to a final density of 500 cells / well and cultured in an incubator (37°C, 5% carbon dioxide). After 72 hours of incubation, 20 μL of Cell Titer-Glo Luminescent Cell Viability Assay solution was added to each well and incubated at room temperature for approximately 30 minutes. The luminescence of each well was measured using EnVision TM (PerkinElmer Inc., MA, USA). The ATP content of the DMSO-treated control group was taken as 100%, and the ratio of the remaining ATP content of each treatment group was determined. The growth inhibition curves of compound 1 in RNASEH2A KO TK-6 cells and their corresponding parental TK-6 cells were plotted using GraphPad Prism (GraphPad Software, Inc., CA, USA) and are shown in Figure 9. This experiment revealed that RNASEH2A KO TK-6 cells were more sensitive to compound 1 than WT TK-6 cells.
Claims
1. Compound 1 【Chemistry 1】 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof; and one or more DNA damaging agents selected from mitomycin C, teniposide, topotecan hydrochloride, carboplatin, decitabine, and melphalan, The cancer is not homologous recombination deficient (HRD); composition.
2. The composition of claim 1, wherein the cancer is resistant to platinum compounds.
3. 2. The composition of claim 1, wherein the cancer is lung cancer, colorectal cancer, pancreatic cancer, or ovarian cancer.
4. The patient to be treated has a mutated and / or deleted gene, and the mutated and / or deleted gene is selected from the group consisting of ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E2F4, ERCC4, ESCO2, FAF1, FANCD2, FANCG, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, KMT2E , KPNA2, MAD2L2, MAP3K7, MLLT1, MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1 and ZNF638.
5. The composition described in claim 4, wherein the mutated and / or deleted gene is selected from RNASEH2A, RNASEH2B and RNASEH2C.
6. A composition described in any one of claims 1 to 3, wherein the DNA damaging agent is mitomycin C.
7. A composition described in any one of claims 1 to 3, wherein the DNA damaging agent is teniposide.
8. A composition described in any one of claims 1 to 3, wherein the DNA damaging agent is topotecan hydrochloride.
9. The composition described in any one of claims 1 to 3, wherein the DNA damaging agent is carboplatin.
10. A composition described in any one of claims 1 to 3, wherein the DNA damaging agent is decitabine.
11. A composition described in any one of claims 1 to 3, wherein the DNA damaging agent is melphalan.
12. The composition described in claim 3, wherein the cancer is lung cancer.
13. The composition of claim 3, wherein the cancer is colorectal cancer.
14. The composition described in claim 3, wherein the cancer is pancreatic cancer.
15. The composition described in claim 3, wherein the cancer is ovarian cancer.
16. 2. The method of claim 1, further comprising administering to said patient a compound of formula (I) or (II) ... 【Chemistry 2】 and / or a tautomer thereof or a pharma- ceutically acceptable salt or hydrate thereof, the DNA damaging agent comprises mitomycin C, teniposide, topotecan hydrochloride, carboplatin, decitabine or melphalan, and The cancer is not homologous recombination deficient (HRD); use.
17. The patient to be treated has a mutated and / or deleted gene, and the mutated and / or deleted gene is selected from the group consisting of ALKBH6, APEX1, APEX2, ARFGEF1, ASF1A, ASF1B, ATRX, BAZ1B, C21orf2, CAV1, CDC25B, CDK19, CDKN1B, CNOT2, CNOT4, DBF4, DDX5, E2F4, ERCC4, ESCO2, FAF1, FANCD2, FANCG, FANCI, FANCL, FBXO5, FBXW7, FOXM1, GMNN, HIST1H3G, IKZF2, ITGB6, 17. The use of claim 16, selected from KMT2E, KPNA2, MAD2L2, MAP3K7, MLLT1, MTBP, NAE1, NHEJ1, POLA2, POT1, PPP2R5D, PPP4R2, PSMC3IP, PUS1, RAD54L, RFWD3, RNASEH2A, RNASEH2B, RNASEH2C, RNF8, RTEL1, SMARCA4, STK11, TAOK3, TICRR, TIPIN, UBE2A, UBE2C, UHRF1, UNG, USP1, USP37, USP7, VRK1, WEE1, XRCC1 and ZNF638.
18. The use described in claim 17, wherein the mutated and / or deleted gene is selected from RNASEH2A, RNASEH2B and RNASEH2C.
19. The use of claim 16, wherein the DNA damaging agent is mitomycin C.
20. The use of claim 16, wherein the DNA damaging agent is teniposide.
21. The use of claim 16, wherein the DNA damaging agent is topotecan hydrochloride.
22. The use of claim 16, wherein the DNA damaging agent is carboplatin.
23. The use of claim 16, wherein the DNA damaging agent is decitabine.
24. The use of claim 16, wherein the DNA damaging agent is melphalan.
25. The use described in claim 16, wherein the cancer is lung cancer.
26. The use described in claim 16, wherein the cancer is colorectal cancer.
Citation Information
Patent Citations
Heterocyclic compound
WO2011102399A1
